Segment Reporting

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Reporting

Note 13. Segment Reporting

The Company operates and manages its business as one reportable and operating segment. The determination of a single operating segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (the “CODM”). The CODM assesses performance for the single segment and decides how to allocate resources based on net loss that also is reported on the statements of operations and comprehensive loss. The monitoring of budgeted versus actual results are used in assessing performance of the segment, and making operating decisions, allocating resources, and planning and forecasting for future periods. The measure of segment assets is reported on the balance sheets as total assets.

In addition to the significant expense categories included within net loss presented on the statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses:

	Year Ended
	December 31,
	2024		2023
External research and development expenses:
Clinical trials expenses	$	15,626	$	21,200
Consulting and outside services		4,707		4,770
Other external research and development (1)		6,911		12,340
Total external research and development expenses		27,244		38,310
Internal research and development expenses:
Personnel related expenses		13,244		16,561
Total research and development expenses	$	40,488	$	54,871

(1) Chemistry manufacturing controls, research and preclinical studies and other miscellaneous expenses.